MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
NCT02085070
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
65
Enrollment
OTHER
Sponsor class
Conditions
Melanoma
Non-Small Cell Lung Cancer
Brain Metastases
Interventions
DRUG:
MK-3475
Sponsor
Yale University